Guggenheim Capital LLC Madrigal Pharmaceuticals, Inc. Transaction History

Guggenheim Capital LLC

$14 Billion
Q3 2024

A detailed history of Guggenheim Capital LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 3,646 shares of MDGL stock, worth $1.14 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,646

Previous 3,335 9.33%

Holding current value

$1.14 Million

Previous $934,000 17.24%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$212.22 - $292.96 $66,000 - $91,110	311 Added 9.33%	3,646 $773,000
Q2 2024 Aug 14, 2024	BUY	$193.33 - $291.99 $70,565 - $106,576	365 Added 12.29%	3,335 $934,000
Q1 2024 May 14, 2024	SELL	$171.37 - $283.23 $77,287 - $127,736	-451 Reduced 13.18%	2,970 $793,000
Q4 2023 Feb 14, 2024	BUY	$120.4 - $237.13 $34,193 - $67,344	284 Added 9.05%	3,421 $791,000
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $62,943 - $97,311	431 Added 15.93%	3,137 $458,000
Q2 2023 Aug 11, 2023	SELL	$203.88 - $312.0 $87,872 - $134,472	-431 Reduced 13.74%	2,706 $625,000
Q1 2023 May 10, 2023	BUY	$231.06 - $307.08 $724,835 - $963,309	3,137 New	3,137 $759,000
Q4 2019 Feb 14, 2020	SELL	$84.28 - $118.5 $1.35 Million - $1.9 Million	-16,064 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$84.4 - $106.53 $88,029 - $111,110	-1,043 Reduced 6.1%	16,064 $1.39 Million
Q2 2019 Aug 14, 2019	BUY	$91.13 - $142.5 $84,386 - $131,955	926 Added 5.72%	17,107 $1.79 Million
Q1 2019 May 15, 2019	SELL	$103.48 - $143.84 $167,844 - $233,308	-1,622 Reduced 9.11%	16,181 $2.03 Million
Q4 2018 Feb 14, 2019	BUY	$94.77 - $215.54 $1.69 Million - $3.84 Million	17,803 New	17,803 $2.01 Million

Others Institutions Holding MDGL

# of Institutions

297

Shares Held

22M

Call Options Held

819K

Put Options Held

640K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.37B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Account

Guggenheim Capital LLC Madrigal Pharmaceuticals, Inc. Transaction History